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PURPOSE. To investigate the neuroprotective properties of creatine in the retina using in vitro
and in vivo models of injury.
METHODS. Two different rat retinal culture systems (one containing retinal ganglion cells
[RGC] and one not) were subjected to either metabolic stress, via treatments with the
mitochondrial complex IV inhibitor sodium azide, or excitotoxic stress, via treatment with N-
methyl-D-aspartate for 24 hours, in the presence or absence of creatine (0.5, 1.0, and 5.0 mM).
Neuronal survival was assessed by immunolabeling for cell-specific antigens. Putative
mechanisms of creatine action were investigated in vitro. Expression of creatine kinase (CK)
isoenzymes in the rat retina was examined using Western blotting and immunohistochemistry.
The effect of oral creatine supplementation (2%, wt/wt) on retinal and blood creatine levels
was determined as well as RGC survival in rats treated with N-methyl-D-aspartate (NMDA; 10
nmol) or high IOP-induced ischemia reperfusion.
RESULTS. Creatine significantly prevented neuronal death induced by sodium azide and NMDA
in both culture systems. Creatine administration did not alter cellular adenosine triphosphate
(ATP). Inhibition of CK blocked the protective effect of creatine. Retinal neurons, including
RGCs, expressed predominantly mitochondrial CK isoforms, while glial cells expressed
exclusively cytoplasmic CKs. In vivo, NMDA and ischemia reperfusion caused substantial loss
of RGCs. Creatine supplementation led to elevated blood and retinal levels of this compound
but did not significantly augment RGC survival in either model.
CONCLUSIONS. Creatine increased neuronal survival in retinal cultures; however, no significant
protection of RGCs was evident in vivo, despite elevated levels of this compound being
present in the retina after oral supplementation.
Keywords: creatine, neuroprotection, retina, creatine kinase, retinal ganglion cell, culture,
ischemia-reperfusion, excitotoxicity, oxidative stress
A number of common blinding diseases, such as glaucoma,diabetic retinopathy, and ischemic optic neuropathy,
include bioenergetic compromise as a likely pathogenic
component. At the molecular level such an energy failure can
instigate a complex series of cellular events, including
membrane depolarization, Ca2þ influx, oxidative stress, mito-
chondrial dysfunction, excitotoxicity and, even, ultimately, cell
death.1–3
Bioenergetic-based neuroprotection refers to the concept
of protecting injured and threatened neurons by strategies,
including increasing their available energy supply, conserving
their fuel reserves, improving their mitochondrial function, or
augmenting their cellular energy buffering.4 Enhancement of
cellular energy metabolism has been attempted with variable
success in a range of neurologic disorders, such as Alzheimer’s
disease,5 Huntingdon’s disease,6 and Parkinson’s disease.7
More pertinently, this approach to neuroprotection has been
targeted to the retina in glaucoma.4 Nicotinamide, for
example, which acts as a substrate for Complex I in the
respiratory chain, and also acts as a free-radical scavenger and
an inhibitor of poly-adenosine diphosphate (ADP)-ribose
polymerase, attenuated ischemic injury to retinal ganglion
cells (RGCs).8 Another compound, coenzyme Q10, a potent
antioxidant and a component of the mitochondrial respiratory
chain has been shown to be neuroprotective against in IOP-
induced retinal ischemia-reperfusion injury.9–11 Additional
findings of relevance to bioenergetic neuroprotection of the
retina are that short-term hyperglycemia, as well as local
administration of glucose, attenuate RGC injury in models of
experimental glaucoma, ischemia reperfusion, and chronic
hypoperfusion.12–15
Creatine, a guanidine compound that occurs naturally in
vertebrates, plays a central role in cellular adenosine triphos-
phate (ATP) buffering, in concert with its phosphorylated form,
phosphocreatine. Creatine and phosphocreatine are intercon-
verted by creatine kinase (CK), an enzyme family comprising
separate isoenzymes based either in mitochondria or the
cytoplasm. Mitochondrial CK converts creatine to phosphocre-
atine at the site of ATP production, with a concurrent
production of ADP. Phosphocreatine has much greater intra-
cellular mobility than adenine nucleotides and this compound
is therefore more readily able to translocate from the
mitochondrion to sites of energy use. Here, cytoplasmic CK
catalyzes the donation of its phosphate group to ADP, thus
reforming ATP and creatine. This cycle is responsible for
buffering of ATP/ADP levels, aiding maintenance of a cellular
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energy reserve and allowing the easy shuttling of fuel currency
between mitochondrial sites of production and cytosolic sites
of use.16,17
Creatine, therefore, possesses a variety of properties, which
could contribute to a potential bioenergetic neuroprotective
action, including being able to buffer intracellular energy
reserves, stabilize intracellular calcium flux, inhibit mitochon-
drial permeability transition, and counteract oxidative stress
build-up.18,19 In fact, creatine supplementation has indeed
been shown to exert neuroprotective effects in both in vitro
and in vivo models of major neurodegenerative conditions,
including models of Huntington’s disease, Parkinson’s disease,
and amyotrophic lateral sclerosis.18,20 To date, there are no
studies that have examined the direct neuroprotective efficacy
of creatine in acute or chronic paradigms of RGC neurodegen-
eration. However, S-adenosyl-L-methionine, which is a biosyn-
thetic precursor of creatine, was able to restore photoreceptor
function in a rat model of retinal ischemia.21 The present study
aimed to assess the neuroprotective properties of creatine in
different retinal models of neuronal compromise: retinal
neurons in culture subjected to excitotoxic challenge or
metabolic impairment and rat retinas subjected to excitotoxic
or ischemic insults in vivo.
MATERIALS AND METHODS
Experimental Design
There were two phases to the overall study as follows: (1) to
assess the effect of creatine in culture preparations exposed to
either energetic compromise with the mitochondrial complex
IV inhibitor, sodium azide, or excitotoxic injury with the
ionotropic glutamate receptor agonist, N-methyl-D-aspartate
(NMDA); and (2) to assess putative neuroprotective effects of
creatine in rat in vivo models of retinal ischemia reperfusion
and NMDA-induced excitotoxicity.
Materials
General cell culture media and reagents, including fetal
bovine serum (FBS), were obtained from Invitrogen (Mul-
grave, Victoria, Australia). Culture vessels (flasks and plates)
and polypropylene centrifuge tubes of all sizes were from
Sarstedt Pty (Adelaide, South Australia, Australia). All other
chemical reagents, except where noted, were from Sigma-
Aldrich Chemical Company (Castle Hill, New South Wales,
Australia).
Animals
This study was approved by the Animal Ethics Committees of
SA Pathology/Central Adelaide Local Health Network and The
University of Adelaide and conformed to both the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes (2013) and the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthal-
mic and Vision Research. All animals were obtained from the
University of Adelaide, South Australia. For culture studies,
Sprague-Dawley rat litters (2–4 days postpartum, average of 8–
12 pups per litter) were obtained and for the in vivo
experiments, adult Sprague-Dawley rats (8–10 weeks) were
used.
Mixed Retinal Cell Culture
Rat retinal cell cultures comprising glia, photoreceptors, and
neurons, but not, generally RGCs, were prepared from the
pups via a trypsin- and mechanical-digest procedure.22 After
tissue dissociation, cells were dispensed onto 13-mm diameter
borosilicate glass coverslips coated previously with poly-L-
lysine (10 lg/mL, 15 minutes) in 24-well culture plates for
immunocytochemical, fluorescent dye-labeling, or apoptotic
analyses. Mean cell density at seeding was approximately 0.5 3
106 cells/mL. Subsequently, cultures were grown at 378C in a
humidified incubator with 5% CO2 in growth medium (MEM
containing 10% FBS, 91 mg/L gentamicin sulphate, 2.3 mg/L
amphotericin B, and 25 mM glucose).
After 6 days in vitro, medium was changed and the cultures
were incubated for 24 hours with either creatine (concentra-
tions of 0.5, 1, and 5 mM) or standard medium (control group).
To establish mitochondrial compromise, some of both the
creatine-treated group and the control group were subjected to
concurrent incubation for 24 hours with 1 mM NaN3 or for 1
hour with 10 mM NaN3. To establish excitotoxicity, after
creatine pretreatment, cells were exposed to 200 lM NMDA
plus 10 mM CaCl2 for 24 hours. At the conclusion of the period
of cell stress, cultures were fixed in 10% (wt/vol) neutral-
buffered formalin in 0.1 M phosphate buffer, pH 7.4 (NBF) for
immunocytochemical analysis. In some cases, incubations
were carried out in the presence of the specific CK inhibitor,
2,4-dinitro-1-fluorobenzene (DNFB; 10 lM), to determine
whether this enzyme was responsible for the observed actions
of creatine.
Retinal Ganglion Cell–Containing Culture System
Retinal neuron cultures containing ganglion cells were
essentially established as described previously.23 Adult
Sprague-Dawley rats were euthanized and eyes were enucle-
ated and placed into PBS containing 100 U/mL penicillin/
streptomycin. Retinas were removed and chopped into small
pieces with dissecting spring scissors. Tissue pieces were
incubated in activated papain (2 mg/mL papain, 0.4 mg/mL DL-
cysteine, 0.4 mg/mL BSA, in Neurobasal medium) at 378C for
20 minutes and then washed three times with Neurobasal
medium, before being dissociated by gentle trituration through
fire-polished Pasteur pipettes. Cell suspensions (1 3 106 cells/
well in Tissue Medium: Neurobasal medium plus B27 nutrient
supplement, 100 U/mL penicillin, 100 U/mL streptomycin, 1
mM sodium pyruvate, 2 mM L-glutamine, 5 lg/mL insulin, 100
lg/mL transferrin, 100 lg/mL BSA, 60 ng/mL progesterone, 16
lg/mL putrescine, 40 ng/mL sodium selenite, 40 ng/mL L-
thyroxine, 40 ng/mL tri-iodothyronine, 5 lg/mL forskolin, 50
ng/mL BDNF, 10 ng/mL ciliary neurotrophic factor, 10 ng/mL
BFGF and 1% [vol/vol] BSA) were dispensed onto 13-mm
borosilicate glass coverslips precoated sequentially with 5 lg/
mL poly-D-lysine (overnight) and 1 lg/mL laminin (2 hours).
Cells were cultured for 14 days before treatments were
established, with half medium changes every 5 days.
After treatments had been carried out for the appropriate
times, cultures were fixed for 10 minutes in NBF and cells were
immunocytochemically labeled for dendrites (MAP2) and
axons (tau); DAPI was applied to label cell nuclei. When
quantification was undertaken, only tau-immunoreactivity (-IR)
was determined.
Animal Models of Retinal Ischemia-Reperfusion
and Excitotoxicity
For establishment of both retinal ischemia reperfusion and
NMDA-induced excitotoxicity, rats were randomly assigned to
either a treatment group, which received 2% oral creatine
supplementation in their feed (20 g/kg) for 4 to 6 weeks prior
to commencement of experiments, or to a control group,
which received standard normal chow throughout the
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experiment (n¼ 8 control, n¼ 7 creatine for retinal ischemia;
n¼ 15 control, n ¼ 18 creatine for NMDA).
For establishment of retinal ischemia in rats, the left eye was
cannulated with a 32-G needle attached to a reservoir
containing sterile 0.9% (wt/vol) NaCl. The IOP was elevated
to 120 mm Hg, which rendered the retina ischemic as
evidenced by fundus pallor. This was maintained for 75
minutes. All rats were killed at 7 days following retinal
ischemia and their eyes removed for analysis.
To produce retinal excitotoxicity, the left eyes of rats were
subjected to an intravitreal injection (using a 32-G needle) of
10 nmol of NMDA (4-lL injected volume), under observation
with a dissecting microscope. All rats were killed at 7 days
following NMDA administration and their eyes removed for
analysis. To assess the effect of creatine on neuronal apoptosis,
separate groups of NMDA-treated animals (n¼ 8 control, n¼ 8
creatine) were killed at 8 hours following injection and their
retinae processed for TUNEL labeling. The right eye in each
animal was used as a control.
Electroretinography
Rats assigned to the retinal ischemia group had scotopic ERG
readings recorded from both eyes before ischemia (baseline)
and 3 and 7 days after reperfusion. To undertake this
procedure, rats were dark-adapted overnight and anaesthetized
briefly with an intraperitoneal injection of ketamine (100 mg/
kg) and xylazine (10 mg/kg). Pupils were dilated with 1%
tropicamide. Eyes were further anaesthetized with 0.04%
oxybuprocaine hydrochloride. Poly Gel lubricating eye gel
(Alcon, Fort Worth, TX, USA) was applied to the cornea before
applying the corneal electrode, reference electrode (connected
to the ipsilateral ear), and ground electrode (on midline dorsal
cephalad). ERGs were recorded after 12 hours of dark
adaptation under general anesthesia and all experimental
procedures were performed under dim red light. The rats
were placed on a heating blanket to maintain body tempera-
ture at 378C. A mixed rod-cone response was obtained using a
photometrically calibrated 10-ls Ganzfeld flash with a 0.75-log
flash intensity (cds/m2). Signals were amplified (gain:1000)
and acquired with a PowerLab 4/35 (ADInstruments, Bella
Vista, NSW, Australia) bioamplifier and data acquisition system
(sampling rate, 1000 Hz) using a band-pass filter between 0.3
and 500 Hz and analyzed with LabChart software (ADInstru-
ments). The a-wave amplitude was measured from the
prestimulus potential to its trough and the b-wave amplitude
from the a-wave trough to the b-wave peak. Ten consecutive
responses were recorded and averaged for each animal.
Immunocytochemistry and
Immunohistochemistry
Retinal cells in culture were fixed with 10% (wt/vol) NBF
containing 1% (vol/vol) methanol for 15 minutes and then
washed in standard PBS. Cells on coverslips were permeabi-
lized with PBS containing 0.1% Triton X-100 (PBST-0.1%),
followed by further washing in PBS and then blocking in PBS
containing 3% normal horse serum (PBS-HS). After overnight
incubation with primary antibodies against calretinin and c-
amino butyric acid (GABA; see Table 1 for antibody details),
coverslips were incubated with biotinylated anti-mouse sec-
ondary antibody (1:250) plus AlexaFluor 488-conjugated anti-
rabbit secondary antibody (1:250; Invitrogen), followed by
streptavidin-conjugated AlexaFluor 594 (1:500) for 1 hour.
Finally, cells on coverslips were mounted using anti-fade
mounting medium (DAKO; Botany Bay, New South Wales,
Australia) and examined under a confocal fluorescence
microscope.
For in vivo experiments, all rats were killed by transcardial
perfusion with physiologic saline. Whole eyes with optic nerve
attached were removed and fixed with NBF for 24 hours at
room temperature. For wholemount immunochemistry, poste-
rior eye cups were dissected and each retina was prepared as a
flattened wholemount via four relaxing incisions. Retinas were
permeabilized with PBS containing 1% Triton X-100, blocked in
PBST-1% containing 3% normal horse serum, then incubated
overnight at 48C in the same solution containing anti-Brn3a and
anti-c-synuclein primary antibodies (see Table 1). After washing
with PBS, wholemounts were incubated with anti-goat Alexa
Fluor 594 conjugate and anti-mouse Alexa Fluor 488 conjugate
for 3 hours at room temperature, before rinsing in PBS and
mounting using anti-fade mounting medium. Slides were
examined under a confocal fluorescence microscope. Immu-
nochemistry on transverse sections was achieved as described
previously.24 In brief, eyes were processed for routine paraffin-
embedded sections, embedded sagitally, and 5-lm serial
sections were cut. Sections were deparaffinized, endogenous
peroxidase activity was blocked, and tissue subjected to high-
temperature antigen retrieval. Sections were then blocked in
PBS-HS and incubated overnight at room temperature with
primary antibodies, followed by consecutive incubations with
biotinylated secondary antibody and streptavidin-peroxidase
conjugate. Color development was achieved using 3 0,3 0-
diaminobenzidine. Sections were counterstained with hema-
toxylin, dehydrated, and mounted. Confirmation of the
specificity of antibody labeling was judged by the morphology
and distribution of the labeled cells, by the absence of signal
when the primary antibody was replaced by isotype/serum
controls, and by comparison with the expected staining
pattern based on our own, and other, previously published
results.
Electrophoresis and Western Immunoblotting
Tissue samples for electrophoresis were prepared from freshly
killed adult Sprague-Dawley rats. Samples of heart, brain
cortex, skeletal muscle, and retina were dissected and
solubilized in homogenization buffer (20 mM Tris-HCl, pH
7.4; containing 2 mM EDTA, 0.5 mM EGTA, 1 mM dithiothre-
itol, 50 lg/mL leupeptin, 50 lg/mL pepstatin A, 50 lg/mL
aprotinin, and 0.1 mM phenylmethylsulfonyl fluoride) at a
concentration of 10-mg tissue wet weight per 100 lL of buffer.
An equal volume of sample buffer (62.5 mM Tris-HCl, pH 7.4,
containing 4% [vol/vol] SDS, 10% [vol/vol] glycerol, 10% [vol/
vol] b-mercaptoethanol, and 0.002% [wt/vol] bromophenol
blue) was then added and samples were heated to 808C for 6
minutes. Electrophoresis was performed using 10% denaturing
polyacrylamide gels for protein separation. After electropho-
resis, proteins were transferred to polyvinylidine fluoride
(PVDF) membranes (Bio-Rad, Hercules, CA, USA) for immuno-
detection. Membranes were blocked in tris-buffered saline
(TBS; 10 mM Tris-HCl, pH 7.4, 140 mM NaCl plus 0.1% [vol/
vol] Tween 20 [TBST] containing 5% [wt/vol] non-fat dried
skimmed milk powder [TBST-NDSM]) before being incubated
with the appropriate primary antibodies (see Table 1), diluted
in TBST-NDSM for 3 hours at room temperature. Relevant
biotinylated secondary antibodies (1:1000 for 30 minutes;
Vector Laboratories, Inc., Burlingame, CA, USA) were applied
followed by streptavidin horseradish peroxidase conjugate
(1:1000 for 1 hour; Thermo Scientific Pierce Protein Biology,
Waltham, MA, USA). Chromogenic detection of antibody
labeling was achieved using 3-amino-9-ethylcarbazole. Reac-
tions were stopped by immersion of membranes in 0.01% (wt/
vol) sodium azide. Detection of histone H3 was assessed in all
samples to normalize total protein levels. Labeled membranes
were scanned with a conventional flat-bed scanner.
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TUNEL
TUNEL was performed according to previously described.25
Retinal wholemounts were prepared as previously described.
These were permeabilized with PBS containing 3% Triton X-
100 for 30 minutes, treated with proteinase K (10 lg/mL in
PBS; Sigma Aldrich) for 10 minutes at 378C and blocked in
PBST-1% containing 3% normal horse serum. The transferase
reaction was performed by incubating retinal wholemounts in
TdT buffer (30 mM Tris-HCl, pH7.2, containing 140 mM
sodium cacodylate and 1 mM cobalt chloride) overnight at
room temperature, with added 0.5 U/lL and 10 lM biotin-16-
dUTP. Reaction was stopped with saline sodium citrate buffer
(300 mM NaCl, 30 mM sodium citrate) for 2 3 15 minutes
before blocking reaction with PBS-HS. For visualization, the
wholemounts were incubated with streptavidin-Alexa Fluor
594 or 488 (1:500), as appropriate, for 3 hours before being
mounted using anti-fade mounting medium.
Assessment of Cellular Levels of Peroxide in Culture
For determination of reactive oxygen species (ROS) levels in
cultures, the ROS-Glo H2O2 Assay Kit (Promega, Madison, WI,
USA) was used as per the manufacturer’s protocol. Briefly,
incubations of cells with creatine (pretreatment for 24 hours
with 5 mM creatine) and nontreated controls (standard medium)
were established as described above except that cultures were
also incubated with H2O2 substrates simultaneously with
sodium azide (1 mM) for 1 hour. H2O2 substrates react with
H2O2 in the media to produce luciferin precursors. The medium
in the 24-well plates was then transferred to 96-well plates and
mixed with an equal amount of ROS-Glo Detection Solution (D-
cysteine and luciferase; 50 lL each) for 20 minutes to produce
luciferin molecules that react with luciferase to generate a
luminescent signal, which is proportional to the H2O2
concentration. Luminescence was quantified by spectroscopy
using a luminometric plate reader (Fluostar Optima; BMG
Labtech, Mornington, Victoria, Australia). For quantification,
luminescence readings (expressed as luminescence units) from
three individual coverslips per data point were averaged.
Assessment of Cellular ATP Content
For determination of ATP levels in culture, a firefly biolumi-
nescence assay kit from Sigma-Aldrich Chemical Company was
used. Cell samples were obtained by removing culture medium
and extracting cellular contents, including ATP, into hot (658C)
distilled water for 5 minutes to denature ATP-metabolizing
enzymes. ATP levels were then determined in comparison with
a standard curve using a luciferin-luciferase assay on a
luminometer (Fluostar Optima).
Creatine Tissue Assay
Levels of creatine were assessed in retinal homogenates and in
blood plasma using a kit supplied by Sigma-Aldrich (product
#MAK079). Retinal samples were prepared by rapid homoge-
nization in four volumes of cold kit assay buffer, followed by
centrifugation at 13,000g for 10 minutes at 48C because high
concentrations of proteins can interfere with the assay, retinal
supernatants, and blood serum samples were spun again on 10
kDa MW cut-off spin filters (VivaSpin 500; Sigma-Aldrich).
Samples were then assayed as per kit instructions, in assay
buffer, in the presence of creatinase, by incubating all
components together for 1 hour at 378C. Suitable controls
and blanks were established (as per kit instructions) and
readings obtained after colorimetric assessment at 570 nm
using a Fluostar Optima automated microplate reader with its
own associated software package (BMG LabTech Pty Ltd.,
Mornington, Victoria, Australia). Creatine concentrations were
calculated against a creatine standard curve and data expressed
as nanogram per microliter of supernatant/serum. Twelve
animals were used to obtain assay data as follows: six animals
had been fed on normal chow and six on creatine-supple-
mented diet for 4 weeks.
Quantification of Retinal Neuronal Survival
To quantify neuronal survival in retinal cultures, images were
captured using an Olympus DP73 scientific grade (Olympus,
Tokyo, Japan), cooled CCD camera mounted on an Olympus
TABLE 1. Antibodies Used in the Study
Name Cat N/Clone* Host Company Dilution
Brn 3a C-20* Goat Santa Cruz 1:3000, 1:600†
c-Synuclein CPTC-SNCG-1 Mouse DSHB‡ 1:40, 1:100†
Calretinin Mab 1568 Mouse Millipore 1:1000
GABA A2052 Rabbit Sigma-Aldrich 1:1000
Histone H3 D1H2* Rabbit CST 1:10000
Glutamine synthetase 610517 Mouse BD Transduction 1:1000
CHX10 Ab 9016 Sheep Millipore 1:10000
Neurofilament-light chain (NFL) Mab 1615 Mouse Millipore 1:5000
PKCa MC5* Mouse Abcam 1:1000
RBPMS ABN1362 Rabbit Millipore 1:2000
S100 Mab 079-1 Mouse Millipore 1:1000
Synaptophysin A0010 Rabbit Dako 1:2000
Syntaxin-1 HPC-1* Mouse Sigma-Aldrich 1:2000
CK-B Ab 125114 Mouse Abcam 1:500/1:2000
CK-M C-4* Mouse Santa Cruz 1:2000
CK-MT1A 15346-1-AP Rabbit Proteintech 1:5000
CK-MT1B Ab 204114 Rabbit Abcam 1:2000
Antibody manufacturer locations: Santa Cruz (Dallas, TX, USA); Millipore (Burlington, MA, USA); Sigma-Aldrich (St. Louis, MO, USA); CST
(Danvers, MA, USA); BD Transduction (San Jose, CA, USA); Abcam (Cambridge, UK); Dako (Santa Clara, CA, USA); Proteintech (Rosemont, IL, USA).
* Indicates clone number of cell line.
† Wholemount immunohistochemistry.
‡ From the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of
Biology (Iowa City, IA, USA).
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BX61 microscope with an epifluorescence attachment. In the
case of calretinin-IR and GABA-IR neurons, counting was
undertaken manually as numbers per microscopic field using a
cell counter. Quantification of tau-IR neurons in mixed cultures
or RGC cultures was carried out using ImageJ software (http://
imagej.nih.gov/ij/; provided in the public domain by the
National Institutes of Health, Bethesda, MD, USA). Images
were converted to grayscale, inverted, and threshold-adjusted.
Positive tau-immunolabeling was thus represented as red pixels
on a white background and this was quantified as proportion
of each image/captured field that was labeled. Counting was
undertaken for five random fields per coverslip and on six to
eight individual coverslips per treatment. Counts were
expressed as percentages of nontreated (without NMDA or
NaN3) cells. Culture data were analyzed for significance using
1-way ANOVA followed by Tukey multiple-comparison test.
For retinal wholemounts, in each of the four quadrants,
three rectangular areas (central, mid, and peripheral) each at
1.2, 1.9, and 2.6 mm from the optic disc were analyzed,
yielding 12 separate retinal areas for counting. Each rectangu-
lar area measured 1.40 3 1.08 mm. RGC counts for whole-
mounts were expressed as percent of control eyes; TUNEL
counts were expressed as counts of positively labeled cells per
observed retinal field. Quantification was performed by
masked observers. Data from wholemounts were analyzed
using Student’s t-test (normal diet versus creatine). A P value of
< 0.05 was considered significant.
RESULTS
Effect of Creatine on Sodium Azide-Induced
Neuronal Loss in Retinal Cultures Lacking
Ganglion Cells
Incubation of mixed retinal cultures with creatine alone at
different concentrations (0.5, 1, and 5 mM) had no detrimental
effect upon the numbers of calretinin- and GABA-positive
neurons (Supplementary Fig. S1). Investigation into whether
creatine augmented neuronal survival during mitochondrial
dysfunction was conducted in both acute and chronic settings,
which was achieved by treatment with the mitochondrial
complex IV inhibitor sodium azide for 1 (10 mM) or 24 hours
(1 mM), respectively.
Treatment with 10 mM sodium azide for 1 hour led to
significant losses of calretinin- (40.1 6 4.8% survival relative to
untreated controls) and GABA-positive (13.9 6 3.0% survival
relative to untreated controls) neurons in the retinal cultures.
Loss of GABA-positive neurons was greater relative to
calretinin-positive neurons. Pretreatment with creatine led to
significantly increased numbers of calretinin-positive neurons
across all three creatine concentrations (Fig. 1; P < 0.01, n ¼
12). For GABAergic neurons, only pretreatment with the
highest concentration of creatine (5 mM) resulted in a
statistically significant increase compared with azide treatment
alone (Fig. 1; P < 0.01, n¼ 13).
In the chronic paradigm of metabolic challenge, treatment
with 1 mM sodium azide for 24 hours resulted in a loss of
calretinin- (28.3 6 1.8% survival relative to untreated controls)
and GABA-positive (2.9 6 0.8% survival relative to untreated
controls) neurons. Pretreatment with creatine led to signifi-
cantly increased numbers of calretinin-positive counts across
all creatine concentrations (Fig. 2; P < 0.05, n ¼ 3). GABA-
immunoreactive neurons were more drastically affected by 24
hours of sodium azide, and pretreatment with creatine failed to
elicit a significant preservation when analyzed by ANOVA
followed by Tukey multiple-comparison test (0.5 mM creatine,
P ¼ 0.78; 1 mM creatine, P ¼ 0.42, 5 mM creatine P ¼ 0.06),
although less conservative tests such as Dunnett’s post hoc test
did reveal a significant protection at the highest concentration
of creatine (5 mM, P ¼ 0.04).
Loss of GABA immunoreactivity is not necessarily indicative
of neuronal viability, as it may simply represent diminished or
altered content of their major cellular neurotransmitter. In
order to better assess actual survival of retinal neurons in the
context of metabolic dysfunction, we quantified the number of
tau-immunoreactive neurons in azide-treated cultures in the
presence or absence of creatine (Fig. 3). Labeling for the
microtubule-associated protein and pan-neuronal marker, tau,
persists until neurons have died. Treatment with 250 lM, 500
lM or 1 mM sodium azide for 24 hours resulted in an
increasing loss of tau-positive neurons (25.0 6 1.3%, 10.3 6
1.6%, 3.8 6 0.2% survival relative to untreated controls,
respectively). Pretreatment with creatine led to significantly
increased numbers of tau-positive cells across the three azide
concentrations (71.3 6 2.4%, 33.8 6 1.7%, 17.1 6 1.4%
survival relative to untreated controls, respectively, P < 0.001,
n¼ 10).
Effect of Creatine Kinase Inhibition on Sodium
Azide-Induced Neuronal Loss in Mixed Retinal
Cultures
Having established that creatine administration promotes
survival of retinal neurons in culture, we next investigated
whether the mechanism of action of creatine was mediated
through creatine kinase, the action of which instigates the
cellular creatine-phosphocreatine energy-buffering system. The
results showed that when the CK inhibitor, DNFB, was
present, the protection by creatine against sodium azide–
induced neuronal toxicity was completely abolished (Table 2).
This was the case for both calretinin- and GABA-positive
neurons and for both the acute (1 hour) and chronic (24 hour)
paradigms. DNFB, furthermore, had no toxic effect over a 24-
hour period on either calretinin- or GABA-positive neurons
when applied to cultures alone (Table 2).
Effect of Creatine on Sodium Azide-Induced ROS
Production in Mixed Retinal Cultures
Creatine itself had no effect on levels of ROS in retinal cultures
(Fig. 4A). In contrast, a 1-hour sodium azide treatment
produced no change in the level of detectable ROS when
applied at 0.1 mM (95.7 6 1.6 of control), a significant
increase in the level of ROS when applied at 1 mM (127.1 6
0.6% of control; *P¼ 0.03) and a reduction in the level of ROS
when applied at 10.0 mM (75.1 6 3.1% of control). However,
the reduction in detectable ROS levels when sodium azide was
applied at 10.0 mM likely reflects the widespread death of cells
caused at this concentration (Fig. 1). Pretreatment with
creatine (5 mM) was able to cause a significant reduction in
azide-stimulated ROS levels both when this latter compound
was applied at 0.1 mM (69.3 6 5.2% of control; *P¼0.037) and
at 1.0 mM (74.6 6 8.2% of control; ***P < 0.001). Creatine did
not affect the levels of ROS detected after treatment with 10.0
mM azide.
Effect of Creatine on Sodium Azide-Induced
Reduction in ATP Content in Mixed Retinal
Cultures
Incubation of retinal cultures with sodium azide (10 mM) for 1
hour caused a reduced level of ATP compared with untreated
controls (Fig. 4B; 55.5 6 13.2%, n ¼ 3). Pretreatment with
creatine (5 mM) had no significant protective effect on the
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FIGURE 2. Effect of creatine on neuronal survival in mixed cultures following a chronic metabolic insult (sodium azide, 1 mM, 24 hours). (A, B)
Calretinin-immunoreactive neurons. (C, D) GABA-immunoreactive neurons. No significant difference was detected in neuron survival after
treatment with different creatine concentrations in the absence of sodium azide. In contrast, pronounced calretinin- and GABA-positive cell loss was
observed in the sodium azide–treated group (A, C, respectively). Pretreatment of neurons with creatine for 24 hours elicited a significant protection
of calretinin-immunoreactive neurons (A, B, 0.5, 1, 5 mM creatine). *P < 0.05 by 1-way ANOVA followed by Tukey multiple-comparison test (n¼3–
4). GABA-immunoreactive neurons were more drastically affected by 24 hours of sodium azide and pretreatment with creatine failed to elicit a
significant preservation when analyzed by Tukey multiple-comparison test (D). Scale bar: 20 lm.
FIGURE 1. Effect of creatine on neuronal survival in mixed rat retinal cultures following an acute metabolic insult (sodium azide, 10 mM, 1 hour).
(A, B) Calretinin-immunoreactive neurons. (C, D) GABA-immunoreactive neurons. No significant difference was detected in neuron survival after
treatment with different creatine concentrations in the absence of sodium azide. In contrast, pronounced calretinin- and GABA-positive cell loss was
observed in the sodium azide–treated group (A, C, respectively). Pretreatment of neurons with creatine for 24 hours elicited significant protection
of both calretinin-immunoreactive neurons (A, B, 0.5, 1, 5 mM creatine) and GABA-immunoreactive neurons (C, D, 5 mM creatine). *P < 0.01 by 1-
way ANOVA followed by Tukey multiple-comparison test (n ¼ 6–13). Scale bar: 20 lm.
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FIGURE 3. Effect of creatine on survival of tau-positive neurons in mixed rat retinal cultures following a chronic metabolic insult (sodium azide, 24
hours). No significant difference was detected in neuron survival after treatment with creatine in the absence of sodium azide (A, B, I). In contrast,
an increasing amount of tau-positive cell loss was detected in the 250-lM, 500-lM, and 1-mM sodium azide–treated groups (C, E, G, I). Pretreatment
of neurons with creatine for 24 hours elicited a significant protection of tau-immunoreactive neurons (D, F, H, I). ***P < 0.001 by Student’s unpaired
t-test with Tukey correction (n¼ 10). Scale bar: 40 lm.
TABLE 2. Effect of Creatine Kinase Inhibition on Protection of Neurons in Culture
Treatment % GABA-Positive Neurons % Calretinin-Positive Neurons
24-hr treatment
Control 100.0 6 6.9 100.0 6 9.6
1 mM Azide 5.3 6 2.0 32.3 6 3.5
Azide þ 5 mM creatine 26.7 6 3.6* 53.7 6 3.3*
10 lM DNFB 102.5 6 7.1 99.7 6 5.9
Azide þ creatine þ DNFB 4.7 6 1.8† 27.1 6 5.1†
1-hr treatment
Control 100.0 6 8.5 100.0 6 9.8
10 mM Azide 18.4 6 4.2 44.4 6 4.7
Azide þ 5 mM creatine 38.2 6 5.4* 71.1 6 7.7*
DNFB 102.9 6 9.8 102.0 6 8.3
Azide þ creatine þ DNFB 16.7 6 3.4† 35.6 6 4.2†
* P < 0.05 compared with azide-treated neurons.
† P < 0.05 compared with neurons treated with azide plus creatine when comparing groups via 1-way ANOVA plus Tukey’s post hoc analysis.
For all treatments, n ¼ 10.
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azide-stimulated reduction in ATP content (47.2 6 5.5%, P ¼
0.59; n¼ 3).
Effect of Creatine on Excitotoxic Death of Retinal
Neurons in Mixed Culture
Having determined that creatine was able to protect retinal
neurons in culture from stress derived from mitochondrial
dysfunction, we sought to examine whether this compound
was protective in a more general sense (i.e., could it protect
against a stressor with a different molecular basis). We
therefore tested whether creatine could prevent neuron loss
as a result of excitotoxicity (Fig. 5), which was induced in
retinal cultures by treatment for 24 hours with 200 lM NMDA
in the presence of 10 mM CaCl2. This excitotoxic challenge led
to significant losses of calretinin-positive (40.0 6 4.0% survival
relative to untreated controls; Figs. 5A, 5B) and GABA-positive
(23.9 6 5.5% survival relative to untreated controls; Figs. 5C,
5D) neurons in the retinal cultures. These reductions could be
completely blocked in the presence of MK801 (10 lM),
confirming that the effect of NMDA was receptor-mediated
(Figs. 5A–D). Creatine (5 mM) was able to reverse the effect of
NMDA on both calretinin- (67.9% 6 6.8% survival relative to
untreated controls, P < 0.05, n¼ 10; Figs. 5A, 5B) and GABA-
immunoreactive (83.9% survival relative to untreated controls
68.9%, P < 0.001, n ¼ 10; Figs. 5C, 5D) neurons. Creatine
did not produce any significant protection of neurons at the
lower concentrations tested (Figs. 6A–D).
Effect of Creatine on Survival of Neurons in
Cultures Containing RGCs
Following identification of the protective influence of creatine
against retinal neurons in vitro, cultures containing retinal
ganglion neurons were established and examined to determine
whether positive effects were specific to the cells present in
the former system or whether they encompassed different
classes of retinal neurons. Comparison of the two systems
showed that, as expected, the major class of neuron group
present in the mixed cultures was the amacrine cell (positive
labeling for the amacrine cell-specific marker, in the retina,
syntaxin-1) while the alternate cultures did, indeed, contain
ganglion cells (as shown by positive labeling for RBPMS,
neurofilament light chain and c-synuclein; double labeling also
shown for tau-immunoreactivity and c-synuclein; Supplemen-
tary Fig. S2). Assessment of the effect of creatine specifically on
neurons in cultures containing RGCs after exposure to sodium
azide or NMDA was therefore subsequently undertaken (Fig.
6). Untreated cultures were generally replete with cells
expressing neurites, including dendrites and axons (Figs. 6A,
6H), and this was unaffected by the presence of creatine alone
(Figs. 6B, 6I, 0.5 mM creatine; Figs. 6C, 6J, 5 mM creatine).
After exposure to either 500 lM sodium azide (Fig. 6D) or 200
lM NMDA (plus 10 mM CaCl2; Fig. 6K) for 24 hours, however,
there were less cells (i.e., less observable perikarya), less
obvious axons, and less dendrites. However, the coincubation
with creatine partially preserved all of these parameters after
treatment with azide (0.5 mM creatine, Fig. 6E; 5 mM creatine,
Fig. 6F) or NMDA (0.5 mM creatine, Fig. 6L; 5.0 mM creatine,
Fig. 6M). Quantification of these effects demonstrated that
creatine at both 0.5 and 5.0 mM produced statistically
significant protection against sodium azide toxicity (Fig. 6G)
and NMDA (Fig. 6N).
Expression of Creatine Kinase Isoforms in the
Retina
Having ascertained that creatine prevented death of retinal
neurons in vitro from both metabolic and excitotoxic insults,
via a mechanism dependent upon CK, we next sought to
examine whether this compound was neuroprotective in the
in vivo setting. Prior to conducting these experiments,
however, it was imperative to characterize the cellular
distribution of CK in the retina, because the presence of a
cellular creatine-phosphocreatine system is essential in order
for any supplemental creatine to be able to provide energy
buffering for neurons. To date, the distributions of CK isoforms
in the rat retina is unknown. CK is an enzyme family
comprising two major isoenzyme subclasses, the cytosolic
isoforms (brain CK, CK-B; muscle CK, CK-M) and the
mitochondrial isoforms (CK-MT1A and CK-MT1B).19
FIGURE 4. Effect of creatine on ROS production and ATP content in
mixed retinal cultures subjected to an acute metabolic insult (sodium
azide, 1 hour). (A) Sodium azide (1 mM) treatment induced an increase
in the level of H2O2 in rat retinal cultures; at 0.1 mM azide produced no
change in ROS, and at 10.0 mM azide produced a decrease in ROS,
likely resulting from the death of cells caused at this concentration.
Coincubation of azide (0.1 or 1.0 mM) with creatine (5 mM) resulted in
significantly reduced H2O2 levels (*P < 0.05 and ***P < 0.001,
respectively, by 1-way ANOVA plus post hoc Tukey’s HSD text; n¼ 4).
(B) Sodium azide (10 mM) treatment induced a decrease in the level of
ATP in rat retinal cultures relative to untreated controls. Coincubation
with creatine (5 mM) had no effect on the level of ATP as altered by
azide (P¼ 0.59 by Student’s unpaired t-test, n ¼ 3).
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By immunohistochemistry, the cytosolic form CK-B was
widely distributed throughout the different cell types of the
retina, as expected (Fig. 7A). Serial dilution of the antibody,
however, revealed that this isoenzyme was most abundant
within macroglial cells, namely Müller cells and astrocytes (Fig.
7B). This pattern of labeling was essentially consistent
throughout the central nervous system, with CK-B preferen-
tially localized to astrocytes of the optic nerve (Fig. 7C) and
brain (Fig. 7D). Double immunolabeling in the retina with S100
(Figs. 7E, 7F) confirmed the predominant glial (Müller cell and
astrocyte) localization of CK-B. In agreement with a glial
localization, CK-B did not colocalize with the synaptic protein,
synaptophysin, and was thus not enriched in neuronal
synapses (Figs. 7G, 7H). The cytosolic isoenzyme CK-M was
highly expressed in extraocular muscle (Figs. 7I, 7J), but the
only other location expressing this enzyme in the retina was
the basolateral surface of the nonneural RPE (Figs. 7K, 7L).
Of the mitochondrial isoforms of CK, CK-MT1A was
present, as expected, throughout heart muscle (Figs. 7P, 7X),
which expresses a large number of mitochondria. In the retina,
CK-MT1A was expressed throughout the optic nerve head,
notably in prelaminar axons (Fig. 7M), and in all layers of the
retina excluding the outer nuclear layer (Figs. 7N, 7O).
Labeling was particularly dense in photoreceptor segments,
in both plexiform layers and in perikarya in the ganglion cell
layer (Fig. 7O), which were proven to be RGCs via double
labeling with Brn3a (Fig. 7Q). In the inner nuclear layer, CK-
MT1A was notable in a discrete population of cells (Fig. 7N).
Double-labeling experiments showed this labeling to be within
the cell bodies of a population of bipolar cells, as CK-MT1A
colocalized with the pan-bipolar cell marker Chx10 in some
cells (Fig. 7S). There was, however, no obvious colocalization
of labeling in any cell bodies in the inner nuclear layer with the
rod bipolar cell marker, PKCa (Fig. 7T), which likely suggests
that the only bipolar cells that express CK-MT1A in their
perikarya are cone bipolar cells. Interestingly and furthermore,
there was no discernible colocalization of CK-MT1A with the
Müller cell–specific protein, glutamine synthetase, in cell
bodies, end-feet, or processes (Fig. 7R). This clearly shows
that CK-MT1A is not expressed at detectable levels in Müller
cells. Results for the alternative mitochondrial CK, CK-MT1B,
in the retina, mirrored that of CK-MT1A, except that labeling
was less abundant. All locations were the same as CK-MT1A,
however, as shown in the optic nerve head (Fig. 7U), retina
(Fig. 7V), RGCs (Fig. 7W), and cardiac muscle (Fig. 7X).
By Western blotting (Fig. 7Y), each of the four CK
antibodies recognized a major protein of the expected
molecular weight in positive-control tissue extracts, namely
heart and brain (CK-MT1A and CK-MT1B), brain (CK-B), and
skeletal muscle (CK-M). In rat retinal extracts, CK-B and CK-
MT1A were abundant, CK-MT1B was detectable but at a lower
level, whilst CK-M was undetectable.
Assessment of Creatine Levels in Retina and Blood
Plasma
After oral supplementation of creatine in feedstock for 4 weeks
(Fig. 8), a statistically significantly elevated level of this additive
was present in both retina (18.9 6 0.9 ng/lL in treated versus
11.9 6 0.9 ng/lL in control) and blood plasma (16.6 6 2.3 ng/
lL in treated versus 2.3 6 1.5 ng/lL in control).
FIGURE 5. Effect of creatine on neuronal death induced by treatment with NMDA (200 lM) in mixed rat retinal cultures. (A, B) The number of
calretinin-positive neurons was markedly reduced by NMDA treatment, which could be reversed entirely by MK801 (10 lM) and partially by
creatine (5 mM). Creatine at 0.5 or 1 mM had no significant effect on negating cell death. (C, D) The number of GABA-immunoreactive neurons
were also reduced by NMDA treatment. Again, this was completely reversed with MK801 and partially reversed by creatine (5 mM). Creatine at 0.5
or 1 mM had no significant effect on protecting these neurons. ***P < 0.001, *P < 0.05, when compared with NMDA-treated values, by 1-way
ANOVA followed by Tukey multiple-comparison test (n ¼ 10 determinations for each). Scale bar: 40 lm.
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Effect of Creatine on Excitotoxicity-Induced RGC
Loss In Vivo
Treatment with NMDA resulted in a significant loss of both
Brn3a- (34.9 6 5.4% survival relative to untreated control eyes)
and c-synuclein-labeled (36.1 6 5.5% survival relative to
untreated control eyes) RGCs after 7 days (Fig. 9). Rats that
underwent prophylactic treatment with creatine showed a
tendency to higher RGC counts (Brn3a-labeled RGCs, 43.9 6
5.2% survival relative to untreated control eyes; c-synuclein-
labeled RGCs, 43.6 6 4.5% survival relative to untreated
control eyes), but the results did not reach statistical
significance for either marker in any of the central, mid, or
peripheral regions analyzed (Brn3a: P¼0.43, P¼0.22, P¼0.15;
c-synuclein: P ¼ 0.35, P ¼ 0.30, P ¼ 0.34; n ¼ 15–18,
respectively).
Effect of Creatine on Excitotoxicity-Induced RGC
Apoptosis In Vivo
While creatine did not reduce the overall level of neuronal
death that occurred 1 week after excitotoxic challenge, it is
conceivable that supplementation may have delayed the onset
of neuronal loss. Thus, we analyzed whether creatine-treated
rats displayed fewer apoptotic nuclei in retinal wholemounts
than rats fed a normal diet, at a time point at which it is known
that apoptosis is widespread in the retina after NMDA injection
(8 hours).26 In NMDA-treated animals, numerous TUNEL-
positive nuclei were detected throughout the retina (Fig. 10;
images shown are from midregion of retinas). The TUNEL-
positive nuclei typically colocalized with shrunken Brn3a-
positive cells (Fig. 10). Quantification of TUNEL-positive cells
revealed no differences between the normal diet (288 6 66
cells) and creatine-fed animals (270 6 50 cells; P¼0.39, n¼8).
Effect of Creatine on Ischemia-Reperfusion-
Induced RGC Loss In Vivo
Finally, we investigated whether creatine supplementation
protected against ischemia reperfusion–induced injury in the
retina, induced via acute elevation of IOP above systolic blood
pressure for 75 minutes. ERG traces recorded from rats at 7
days after ischemia reperfusion showed a substantial loss of the
b-wave, and a moderate decrease in the a-wave, when
compared with baseline (Fig. 11). Treatment with creatine
did not significantly preserve either the b-wave amplitude
(0.15 6 0.02 normal diet versus 0.15 6 0.04 creatine diet; P¼
0.93) or the a-wave amplitude (0.16 6 0.03 normal diet versus
0.15 6 0.03 creatine diet; P ¼ 0.89).
Retinal ischemia reperfusion caused a significant loss of
both Brn3a- (30.4 6 3.8% survival relative to untreated control
FIGURE 6. Effect of creatine against NaN3- (A–G) and NMDA-induced (H, N) toxicity to rat retinal neurons in cultures containing RGCs. Assessment
was made by immunocytochemical labeling (A–F, H–M) of cultured neurons with MAP2 (red labeling; dendrites), tau (green labeling; axons), and
DAPI (blue labelling; nuclei). Quantification of effects was achieved using ImageJ (G, N). A 24-hour treatment with NaN3 (500 lM) induced
widespread damage to neurons, including loss of dendrites, destruction/shortening of axons, and reduction in numbers of cells (D). This was
significantly prevented by creatine at both 0.5 and 5.0 mM (E–G). A 24-hour treatment with 200 lM NMDA was also extremely damaging to cultured
neurons, again causing loss of dendrites, reduction of axons, and loss of whole cells (K, N). Damage to cells was significantly reduced in the
presence of both 0.5 and 5.0 mM creatine (L–N). ***P < 0.001, *P < 0.05, when compared with treated values, by 1-way ANOVA followed by Tukey
multiple-comparison test (n ¼ 6 determinations for each). Scale bar: 40 lm.
Effect of Creatine on Retinal Ganglion Cell Survival IOVS j October 2019 j Vol. 60 j No. 13 j 4369
Downloaded from iovs.arvojournals.org on 12/11/2019
eyes) and c-synuclein-labeled (31.2 6 3.1% survival relative to
untreated control eyes) RGCs after 7 days (Fig. 12). Rats that
underwent prophylactic treatment with creatine showed a
slight tendency to higher RGC counts Brn3a- (32.6 6 7.3%
survival relative to untreated control eyes) and c-synuclein
labeled (35.6 6 6.9%, survival relative to untreated control
eyes), but the results did not reach statistical significance for
either marker in any of the central, mid, or peripheral regions
analyzed (Brn3a: P¼ 0.39, P¼ 0.79, P¼ 0.67; c-synuclein: P¼
0.15, P ¼ 0.49, P ¼ 0.65; n ¼ 7–8).
FIGURE 7. Expression of creatine kinase isoenzymes in rat retinal tissue. (A–L) Representative images of cytosolic creatine kinase isoenzymes in rat
retina, optic nerve, extraocular muscle, and brain, as determined by immunohistochemistry. CK-B was widely distributed throughout the different
cell types of the retina (A). Serial dilution of the antibody, revealed that this isoenzyme was most abundant within Müller cells and astrocytes of the
retina (B), and astrocytes of the optic nerve (C) and brain (D). CK-B co-localized with the Müller cell/astrocyte S100 in the retina (E, F, arrows). In
contrast, CK-B did not obviously colocalize with the synaptic marker synaptophysin in either plexiform layer (G, H). CK-M was highly expressed in
extraocular muscle (I, J), but not within the neural retina. CK-M did, however, localize to the RPE (K, L). Black scale bar, (I)¼ 250 lm; (A, B)¼ 50
lm; (C, D, J, K, L) ¼ 25 lm. White scale bar, (E–H) ¼ 20 lm. (M–X) Representative images of ubiquitous mitochondrial creatine kinase
immunolabeling in rat retina, optic nerve, and heart. In the optic nerve, CK-MT1A was expressed in prelaminar axons (M). In the retina, CK-MT1A
labeling was intense in photoreceptor segments, in both plexiform layers, and in perikarya in the ganglion cell layer (N, O). CK-MT1A labelled
cardiac muscle (P). Double-labeling immunofluorescence revealed colocalization of CK-MT1A with the RGC marker Brn3a (Q), but not with the
Müller cell marker glutamine synthetase (R). In addition, CK-MT1A colocalized with the pan-bipolar cell marker Chx10 (S), but not obviously with
the specific rod bipolar cell marker PKCa (T). CK-MT1B displayed a similar distribution to CK-MT1A in the retina, except that labeling was less
abundant (U–X). Black scale bar, (M, U) ¼ 100 lm; (N, V) ¼ 50 lm; (O, P, W, X) ¼ 25 lm. White scale bar, (Q–T) ¼ 20 lm. (Y) CK isoform
expression, as analyzed by Western immunoblot, in retinal extracts, and extracts of heart, brain, and skeletal muscle. Molecular weight markers
were used to determine the size of detected gel products. For all proteins analyzed, a major band of the expected molecular weight is apparent in
the relevant positive control tissues (see below), confirming the specificity of each antibody for its intended target in the rat. Histone H3 (15 kD),
loading control; CK-MT1A (40 kD), heart, brain; CK-MT1B (40 kD), heart, brain; CK-B (45 kD), brain; CK-M (40 kD), skeletal muscle. In retinal
extracts, a band of the expected molecular weight is observed for CK-MT1A and CK-B, a fainter band is apparent for CK-MT1B, while CK-M was
undetectable. EOM, extraocular muscle; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
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DISCUSSION
Creatine is Neuroprotective Against Mitochondrial
Stress and Excitotoxicity In Vitro
In this study, we conducted experiments to assess whether
creatine was able to protect retinal neurons in cultures lacking
and cultures containing RGCs from insults that detrimentally
affect cellular metabolism or stimulate excitotoxicity. Initial
studies employed a model of metabolic dysfunction induced by
using sodium azide to compromise mitochondrial oxidative
phosphorylation. We have previously determined in rat retinal
cultures that sodium azide reliably induces neuronal loss via
oxidative stress, mitochondrial membrane disruption, and
energetic dysfunction.22 In the present study, sodium azide
caused significant neuronal loss when applied in both acute
and chronic paradigms to mixed cultures. It also caused a
marked degeneration and loss of neurons when applied to
cultures enriched in RGCs for 24 hours. When creatine was
added prophylactically to mixed cultures, a significant and
concentration-dependent neuronal protection was observed
when assessing numbers of both calretinin- and GABA-positive
FIGURE 8. Assessment of creatine levels in blood plasma and within
retinal tissue after dietary supplementation as 2%-enriched feed for 4
weeks. After 4-weeks supplementation in feed, creatine levels were
significantly elevated in both blood plasma and within retinal extracts.
***P < 0.001 when compared with treated values, by unpaired
Student’s t-test analysis (n¼ 6 determinations for each).
FIGURE 9. Effect of creatine supplementation on RGC survival in retinal wholemounts following NMDA-induced excitotoxicity. Intravitreal
injection of NMDA (10 nmol) caused substantial decreases in the numbers of Brn3a- (A, B) and c-synuclein-positive (A, C) RGCs after 7 days. Rats
that underwent prophylactic treatment with creatine showed a tendency to higher RGC counts, but the results did not reach statistical significance
for either marker in any of the central, mid, or peripheral regions analyzed (Brn3a: P¼ 0.43, P¼ 0.22, P¼ 0.15; c-synuclein: P¼ 0.35, P¼ 0.30, P¼
0.34; by Student’s unpaired t-test, where n ¼ 15–18). Scale bar: 100 lm.
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cells. Both calretinin and GABA are reliable markers, which
label distinct neuron sets in rat retinal cultures, both
predominantly label-specific populations of amacrine cells.27,28
In order to confirm a more generic protective effect to
neurons, we also labeled cultures with the pan-neuronal
marker, tau. In agreement with calretinin- and GABA-labeled
neurons, we detected a clear neuroprotective effect of creatine
to tau-labeled neurons subjected to sodium azide–induced
metabolic compromise. Subsequent to these studies we also
showed that creatine was able to proffer a significant
protective effect to RGCs when present in enriched cultures.
The neuronal protections observed in our culture systems
were consistent with other in vitro studies, which have
demonstrated positive effects of creatine in paradigms of
central nervous system neurodegenerative diseases,18,29–32
including against sodium azide–induced metabolic dysfunction
in cortical axons.22 We also found that creatine was able to
protect retinal neurons in both mixed cultures and RGC-
containing cultures from an excitotoxic challenge, as previ-
ously demonstrated by Brewer and colleagues.30 Interestingly,
although superficially manifest via distinct pathways—with
excitotoxicity largely brought about by uncontrolled stimula-
tion of intracellular calcium increases, and mitochondrial
compromise largely brought about by ATP synthesis abridge-
ment—these two insults must share a common mechanism of
toxicity. It is this pathway or process that must be blocked by
the action of creatine.
Mechanisms of Protection
Having shown in our in vitro studies that creatine could protect
neurons in different preparations from different insults;
mechanistically, we showed that it was also able to reduce
oxidative stress. The presented data were in agreement with
previously proposed mechanisms for creatine in studies related
to models of other neurodegenerative diseases.18,29–45 We did
not, however, detect that creatine was able to elevate the level
of cellular ATP. Previous studies have not consistently detected
higher ATP levels in cultured neurons treated with creatine, but
they have suggested a role for creatine in neuroprotection as an
energy buffer. In 2007, Prass and colleagues43 found an
augmented cerebral blood flow and a 40% reduction in infarct
volume in creatine-fed mice in a rodent model of cerebral
ischemia, but no significant increase in ATP content. Conversely,
Wilken and colleagues46 treated rat dams with anoxia for 30
minutes and found that in creatine-fed animals subjected to the
same insult, histologic brain slices of their pups showed a
significantly higher level of ATP. Brewer and colleagues30
incubated hippocampal neurons with creatine and showed
protection against glutamate-induced excitotoxicity, but did not
find a significantly higher ATP level in the neuronal tissues.30
Their study did, however, show that in the early stages of
glutamate exposure, the phosphocreatine-to-ATP ratio was
significantly higher in creatine-treated neurons, although the
creatine level itself was lower. They proposed that this change in
creatine/phosphocreatine ratio was due to initial conversion of
new intracellular creatine to phosphocreatine with the con-
sumption of ATP (and rise in phosphocreatine). Thus, creatine
likely acted as an energy buffer instead of an immediate energy
supply. Furthermore, in models of cellular injury, energy
consumption may easily exceed the ability of the cell to
regenerate high-energy phosphates, hence explaining the lack of
elevation of ATP content in our own and other studies. An
elegant study by Walsh et al.17 provided evidence of a key role
FIGURE 10. Effect of creatine supplementation on TUNEL labeling in retinal wholemounts following NMDA-induced excitotoxicity. (A) Double-
labeling immunofluorescence of TUNEL labelling and Brn3a in retinal wholemounts analyzed 8 hours after intravitreal injection of NMDA; images
represent midpoint regions of the retina. (B) NMDA treatment induced a marked increase in TUNEL labeling, which was not counteracted by
prophylactic treatment with creatine (P ¼ 0.39, by unpaired Student’s t-test; n ¼ 8). Scale bar: 50 lm.
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for both creatine and phosphocreatine in regulation of
metabolism. They showed that creatine augmented mitochon-
drial respiration, which is stimulated by elevated cellular ADP,
but interestingly they also showed that phosphocreatine had an
opposite effect (i.e., it reduced the ADP-induced stimulation of
mitochondrial metabolism). These data inform us that rather
than being purely involved in energy buffering and phosphate
shuttling, the creatine/phosphocreatine ratio can directly affect
the rate of mitochondrial production of ATP. Taking all of this
information into account, the lack of an increased ATP level in
our study may well reflect the fact that creatine-stimulated
mitochondrial respiration, which contributed toward neuropro-
tection, but that this increased mitochondrial output ultimately
reflected elevated phosphocreatine rather than ATP.
An important finding in our study was that the positive
effect of creatine in culture against azide-induced toxicity was
abolished in the presence of a CK inhibitor. Because creatine-
phosphocreatine cycling via CK action is thought to be the
major means by which energy buffering and intracellular
shuttling is achieved,19 this may seem self-evident. However,
inhibiting CK, per se, would not necessarily affect any direct
stimulation of metabolism by creatine, nor would it affect any
antioxidative role for this compound. Further, because
mitochondrial ATP synthesis is drastically limited by azide
treatment, then there would be inadequate phosphocreatine to
shuttle to the cytoplasm. What is likely is that in the azide-
toxicity model, electron transport complex inhibition results in
a stimulation of nonmitochondrial (glycolytic) respiration via
the Warburg effect,47 a conclusion supported by our earlier
work in which we showed that glucose counteracts azide
toxicity to neurons in retinal cultures.22 Thus, the action of
creatine in the azide-induced toxicity model must, first, be
manifest in the cytoplasm and, second, be manifest through
the action of a nonmitochondrial CK. Therefore, we postulate
the importance of the cytoplasmic isoform of CK, acting
independently of the mitochondrial enzyme. This conclusion is
given indirect support by our finding that retinal neurons
express both mitochondrial and cytoplasmic CK isoforms, but
retinal macroglia, including Müller cells and astrocytes, only
express a cytoplasmic form of CK (CK-B). These data together
suggest that neuronal tissues, including the retina, may, in fact,
not use the classically described intracompartmental cellular
creatine-phosphocreatine shuttle.
Creatine Supplementation is Not Neuroprotective
in Models of Ischemia and Excitotoxicity In Vivo
Having observed protection in vitro, via a CK-dependent
mechanism, we next investigated whether creatine was able to
protect retinal neurons in vivo from excitotoxic and ischemia-
reperfusion injuries. Prior to conducting these experiments,
however, we sought to characterize the distributions of the CK
isoforms in the rat retina, which were hitherto unknown. Our
results revealed, as highlighted above, that retinal neurons,
notably photoreceptors, bipolar cells, and RGCs, particularly
express mitochondrial CK isoforms, but retinal macroglia,
FIGURE 11. Representative ERGs recorded prior to- (A), and 7 days after 75 minutes of high IOP-induced retinal ischemia reperfusion (B, C).
Ischemia reperfusion caused decreases in the a- and b-wave amplitudes (D, E). Rats that underwent prophylactic treatment with creatine showed no
preservation of a- or b-wave amplitudes (D, E). I/R, ischemia reperfusion.
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including Müller cells and astrocytes, only express a cytoplas-
mic form of CK (CK-B). The results are in complete agreement
with previous studies in rodent and human brain, which have
shown that mitochondrial CK is expressed exclusively in
neurons, with cytoplasmic CK-B being predominantly localized
to astrocytes.48,49 The intense labeling of RGCs for mitochon-
drial CKs would suggest that the intracellular creatine-
phosphocreatine shuttle plays a key role in regulating energy
metabolism in mitochondria in these cells in vivo. This is an
important finding as both the NMDA-induced excitotoxicity
and high IOP-induced retinal ischemia-reperfusion models of
injury primarily affect the RGC population.2,50–54
To assess RGC survival following excitotoxic and ischemic
injuries, we supplemented the feed of test animals with a 2%
creatine-enriched diet for 4 weeks prior to initiating insults.
After this time, it was noted that retinal and blood plasma
levels of creatine were significantly elevated after oral
supplementation, proving this additive was available within
the tissue after insults had been promulgated. In order
determine RGC protection in in vivo situations, these cells
were immunolabeled for two reliable, well-characterized
markers, Brn3a and c-synuclein.55,56 Surprisingly, feeding rats
a 2% creatine-enriched diet did not result in any significant
protection against loss of RGCs in either model, although there
was a trend of higher numbers of RGCs in both studies. With
each series of experiments, comparisons of the numbers of
remaining RGCs were undertaken after 7 days of treatment, a
time point at which approximately 65% of RGCs had been lost.
In the case of NMDA-induced excitotoxicity, cell death is
known to be rapidly induced within a few hours,26 thus, it was
considered conceivable that creatine may have delayed, but
not prevented, the onset of cell death, such that the effect was
no longer evident at the 7-day time point of analysis.
Accordingly, we also analyzed the effect of creatine on
NMDA-induced RGC death by quantifying the extent of TUNEL
labeling at 8 hours, a time point known to be near to peak of
apoptosis.57 The results showed no difference in the numbers
of TUNEL-positive RGCs between rats fed normal chow and
those on a creatine-enriched diet, data that are consistent with
the quantification of RGC numbers at 7 days.
Our negative results are in contrast to those of Malcon and
colleagues,33 who treated rats with 1% creatine for 1 week
FIGURE 12. Effect of creatine supplementation on RGC survival in retinal wholemounts following ischemia-reperfusion injury. High IOP-induced
retinal ischemia (75 minutes) caused substantial decreases in the numbers of Brn3a- (A, B) and c-synuclein-positive (A, C) RGCs after 7 days. Rats
that underwent prophylactic treatment with creatine showed a tendency to higher RGC counts, but the results did not reach statistical significance
for either marker in any of the central, mid, or peripheral regions analyzed (B, Brn3a: P¼0.39, P¼0.79, P¼0.67; C, c-synuclein: P¼0.15, P¼0.49,
P ¼ 0.65; by Student’s unpaired t-test, where n¼ 7–8). Scale bar: 100 lm.
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before and after subjecting them to intracerebral injection of
NMDA and showed a significant reduction in volume of NMDA-
induced striatal lesions (~20%) in the creatine-treated brains
compared with controls. Conversely, in a recent study,
intracerebral b-amyloid injections were performed on Wistar
rats before feeding these animals on a diet containing 2% (wt/
wt) creatine for a total of 6 weeks. At the end of the
experiment, several tests, including a measure for learning and
memory retrieval as well as TUNEL staining on histologic
sections, did not show any significant difference between the
creatine-treated and control groups.58
Discrepancy Between In Vitro and In Vivo Findings
Mitochondrial compromise via sodium azide, excitotoxicity,
and ischemia-reperfusion all lead to elevated cellular oxidative
stress levels and increased apoptosis.22 It is interesting that
although creatine was able to protect neurons in vitro,
protection was not evident in vivo. One putative explanation
for this discrepancy is that the in vivo models of RGC injury
were too drastic, such that the resultant toxicity overwhelmed
any minor protection afforded by creatine. Both high IOP-
induced retinal ischemia and NMDA-induced retinal excitotox-
icity are acute models of retinal damage, rather than slow-
progressing, chronic diseases, such as glaucoma. If creatine is
neuroprotective, it would arguably be more evident in a model
where damage is less pronounced and of a more protracted
duration. However, previous experiments have demonstrated
neuroprotective efficacy of compounds in these models (e.g.,
betaxolol59), meaning that protection of neurons is possible in
these systems. Another possible explanation for the lack of
neuroprotective effect seen in the animal models is that the
prophylactic treatment regime of creatine, as applied via the
oral route, may not provide a sufficient dose of this compound
in the retina. However, the dosing regimen used herein (2% wt/
wt in chow) is similar to that employed in other neuroprotec-
tion studies in the brain, and assaying for creatine levels after
supplementation clearly showed elevated levels of this additive
in the retina. In a Parkinson model pretreatment of mice with
1% creatine (wt/wt in chow) for 2 weeks prior to N-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine injections almost com-
pletely abolished deleterious effects to dopaminergic neu-
rons.39 Similarly, in studies in a rodent model of amyotrophic
lateral sclerosis, a dose-dependent increase in survival com-
pared with placebo (reduction in neuronal cell death) was
observed with 1% to 2% of creatine (in chow), when started
within 1 to 2 months postpartum.34 Interestingly, Moxon-
Lester and colleagues21 showed that retinal ischemia in rats
leads to rapid and prolonged downregulation of creatine
transporter-1, with eventual recovery by day 10 postischemia.
Creatine transporters are preferentially localized to photore-
ceptor inner segments and neurons in the inner retina,
including amacrine and RGCs, and are required for cellular
uptake of creatine from the blood.60 Therefore, the lack of
protection in our ischemia-reperfusion experiment may be
explained by inadequate uptake of creatine into vulnerable
cells throughout the postinsult period because of creatine
transporter downregulation.
CONCLUSION
In conclusion, prophylactic creatine treatment provided
neuroprotection to retinal neurons in culture by mechanisms
mediated via CK that likely involved reducing oxidative stress.
Yet, creatine was not protective to RGCs in models of
excitotoxicity and ischemia reperfusion in vivo, under the
conditions that were employed here. This discrepancy needs
to be further explored and validated in future studies; for
example, in chronic animal models of RGC damage, for
instance, experimental glaucoma models that induce slow
progressive loss of RGCs.
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